Order Article Reprints

Kita T, Ohmagari N, Saito S, Mukae H, Takazono T, Nakada T-A, Shimada T, Hirai Y, Shindo Y, Komiya K, et al. Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial. Viruses. 2025; 17(7):982. https://doi.org/10.3390/v17070982

Kita, Toshihiro, Norio Ohmagari, Sho Saito, Hiroshi Mukae, Takahiro Takazono, Taka-Aki Nakada, Tadanaga Shimada, Yuji Hirai, Yuichiro Shindo, Kosaku Komiya, and et al. 2025. "Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial" Viruses 17, no. 7: 982. https://doi.org/10.3390/v17070982

Kita, T., Ohmagari, N., Saito, S., Mukae, H., Takazono, T., Nakada, T.-A., Shimada, T., Hirai, Y., Shindo, Y., Komiya, K., Saito, A., Yamato, M., Homma, K., Okamoto, M., Yamamoto, Y., Mutoh, Y., Hasegawa, C., Mori, N., Nakamura-Uchiyama, F., ... Kitamura, K. (2025). Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial. Viruses, 17(7), 982. https://doi.org/10.3390/v17070982